title: Survival analysis of patients with non-small cell lung cancer who underwent surgical resection following 4 lung cancer resection guidelines.
abstract: BACKGROUND
  To compare survival of patients with non-small cell lung cancer (NSCLC) who underwent surgical resection and lymph node sampling based on guidelines proposed by the American College of Surgeons Oncology Group (ACOSOG), National Comprehensive Cancer Network (NCCN), the OSI Pharmaceutical RADIANT trial, and the International Association for the Study of Lung Cancer (IASLC).
  
  
  METHODS
  Medical records of patients with NSCLC who underwent surgical resection from 2001 to 2008 at our hospital were reviewed. Staging was according to the 7th edition of the AJCC TNM classification of lung cancer. Patients who received surgical resection following the IASLC, ACOSOG, RADIANT or NCCN resection criteria were identified.
  
  
  RESULTS
  A total of 2,711 patients (1803 males, 908 females; mean age, 59.6 ± 9.6 years) were included. Multivariate Cox proportional hazards regression analysis indicated that increasing age, adenosquamous histology, and TNM stage II or III were associated with decreased overall survival (OS). Univariate analysis and log-rank test showed that surgical resection following the guidelines proposed by the IASLC, NCCN, ACOSOG, or RADIANT trial was associated with higher cumulative OS rates (relative to resection not following the guidelines). Multivariate analysis revealed that there was a significant improvement in OS only when IASLC resection guidelines (complete resection) were followed (hazard ratio=0.84, 95% confidence interval 0.716 to 0.985, P=0.032).
  
  
  CONCLUSIONS
  Surgical resection following the criteria proposed by IASLC, NCCN, ACOSOG, or the RADIANT trial was associated with a higher cumulative OS rate. However, significant improvement in OS only occurred when IASLC resection guidelines were followed.
authors.forename: Dongsheng
authors.initials: D
authors.lastname: Yue
authors.forename: Liqun
authors.initials: L
authors.lastname: Gong
authors.forename: Jian
authors.initials: J
authors.lastname: You
authors.forename: Yanjun
authors.initials: Y
authors.lastname: Su
authors.forename: Zhenfa
authors.initials: Z
authors.lastname: Zhang
authors.forename: Zhen
authors.initials: Z
authors.lastname: Zhang
authors.forename: Feng
authors.initials: F
authors.lastname: Gu
authors.forename: Meng
authors.initials: M
authors.lastname: Wang
authors.affiliation: Department of Lung Cancer, Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center of Cancer, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, P,R, China. wangchangli@medmail.com.cn.
authors.forename: Changli
authors.initials: C
authors.lastname: Wang
mesh_terms: D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000453:epidemiology* / Q000473:pathology / Q000601:surgery*; D005260:Female; D017408:Guidelines as Topic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008198:Lymph Nodes / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D016019:Survival Analysis